The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Hereditary Angioedema Therapeutics Market At The End Of The 2026–2030 Forecast Period?
The hereditary angioedema therapeutics market has experienced rapid expansion in its size over recent years. It is anticipated to grow from $7.77 billion in 2025 to $9.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. The market’s past growth can be ascribed to several factors, including insufficient awareness regarding hae, a dependence on hospital-centric therapy, a scarcity of approved treatment options, the predominant use of intravenous administration, and low diagnosis rates attributable to its prevalence.
The hereditary angioedema therapeutics market is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $19.03 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 19.7%. This expansion in the forecast period is primarily driven by factors such as the increasing availability of recombinant C1 esterase inhibitors, the growing adoption of subcutaneous delivery methods, an increase in the use of prophylactic therapies, the broadening reach of specialty pharmacy channels, and rising investment in rare disease research. Furthermore, significant trends expected during this period include the advancement of personalized therapies, an increase in orphan drug approvals, continued progress in subcutaneous drug delivery, the creation of on-demand treatment alternatives, and the expansion of both hospital and retail pharmacy networks.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What Drivers Are Shaping The Future Growth Of The Hereditary Angioedema Therapeutics Market?
The rising healthcare expenditure is projected to stimulate the expansion of the hereditary angioedema therapeutics market moving forward. Healthcare expenditure signifies the total resources, including financial provisions, allocated to healthcare goods and services over a specified period within a particular geographical area. Elevated healthcare spending enables greater investment in research and development initiatives aimed at unraveling the fundamental causes of hereditary angioedema and formulating pioneering therapeutic solutions. For example, in June 2025, the Centers for Medicare & Medicaid Services (CMS), a federal agency based in the US, stated that National Health Expenditure (NHE) increased by 7.5% to $4.9 trillion in 2023, amounting to $14,570 per person, and constituted 17.6% of Gross Domestic Product (GDP). Hospital expenditures climbed by 10.4% to $1,519.7 billion in 2023, a quicker pace than the 3.2% growth recorded in 2022. Thus, the escalating healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.
What Segment Types Make Up The Hereditary Angioedema Therapeutics Market?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-Demand
Which Market Trends Are Creating New Opportunities In The Hereditary Angioedema Therapeutics Market?
Leading companies in the hereditary angioedema (HAE) therapeutics market are developing novel treatments, including oral plasma kallikrein inhibitors, to improve patient management and provide effective, on-demand options for alleviating HAE attacks, thereby enhancing overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are medications taken by mouth that block the plasma kallikrein enzyme, assisting in the management and reduction of hereditary angioedema attack severity. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US. Food and Drug Administration of New drug application for Sebetralstat, aiming to offer HAE patients a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution addresses the growing demand for fast, effective oral treatments that can be administered immediately during an hereditary angioedema attack.
Who Are The Key Players Driving Competition In The Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.
Read the full hereditary angioedema therapeutics market report here:
Which Geographic Regions Are Influencing Demand In The Hereditary Angioedema Therapeutics Market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Hereditary Angioedema Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp
Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company
Hereditary Angioedema Therapeutics Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Angina Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model